STOCK TITAN
  1. Home
  2. News
  3. TBPH

Theravance Biopharma Inc - TBPH STOCK NEWS

Welcome to our dedicated news page for Theravance Biopharma (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Theravance Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Theravance Biopharma's position in the market.

News
Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024
Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) to host a virtual KOL event discussing treatment landscape for MSA patients with symptomatic nOH. The event will focus on the clinical development program for ampreloxetine, a potential first-in-class therapy for nOH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
conferences
-
News
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) reported strong financial and operational results for Q4 2023 and full-year 2023. YUPELRI net sales increased by 9% to $60.6 million in Q4, with a full-year revenue of $221 million. The company achieved Non-GAAP profitability in Q4 despite a GAAP net loss of $8.5 million. Additionally, a capital return program reduced shares outstanding by 37%. Ampreloxetine investor event is planned for Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.98%
Tags
earnings
-
News
Theravance Biopharma to Participate in an Upcoming Investor Conference
Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) to participate in CNS Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference. Senior management to host one-on-one meetings. Webcast available on Theravance.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
News
Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
Rhea-AI Summary
Theravance Biopharma, Inc. (TBPH) will release its Q4 and full year 2023 financial results on Feb 26, 2024, followed by a conference call and webcast. Investors can join the call via phone or web to get updates on the company's performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences earnings
-
News
Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Rhea-AI Summary
Theravance Biopharma, ticker symbol TBPH, announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for maintenance treatment of COPD. The study compared YUPELRI to Spiriva HandiHaler in adults with severe to very severe COPD and suboptimal peak inspiratory flow rate (PIFR). While the primary endpoint was not met, YUPELRI demonstrated similar lung function improvement and safety profile consistent with previous clinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.98%
Tags
none
-
News
Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors
Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) appoints Jeremy Grant to its Board of Directors, enters into a cooperation agreement with Irenic Capital, and reaffirms its commitment to maximizing shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
management
News
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference
Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) will have its management team, including CEO Rick E Winningham and CFO Aziz Sawaf, holding investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference from January 8-11, 2024, in San Francisco, CA. Investors can request a one-on-one meeting with the management team by contacting investor.relations@theravance.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
News
Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System
Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) announced a new anchor-based analysis of ampreloxetine data in neurogenic orthostatic hypotension (nOH) at the 34th International Symposium on The Autonomic Nervous System. The analysis underscores the clinical relevance of the Orthostatic Hypotension Symptom Assessment domain of the Orthostatic Hypotension Questionnaire, supporting its use as a primary endpoint in clinical studies. Key observations from the analysis include the identification of clinically meaningful thresholds for improvement and worsening of the OHSA composite score, as well as the demonstration of a 1.6 point benefit of ampreloxetine relative to placebo in MSA patients during the randomized withdrawal period of Study 170.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
-
News
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Theravance Biopharma, Inc. (NASDAQ: TBPH) to participate in Fireside Chat at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
News
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) and Theravance Biopharma, Inc. (NASDAQ: TBPH) announce positive Phase III results for YUPELRI in China, demonstrating efficacy and safety for COPD patients. The study shows a statistically significant increase in trough FEV1 compared to placebo, supporting a regulatory filing in China in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
clinical trial
Stock TBPH logo
Theravance Biopharma Inc

Nasdaq:TBPH

TBPH Rankings

#3068 Ranked by Market Cap
#2644 Ranked by Stock Gains
N/A Ranked by Dividends

TBPH Stock Data

466.66M
15.86M
14.51%
103.35%
15.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Cayman Islands
George Town

About TBPH

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.